福泰制药

最新新闻

• BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $665
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• UBS Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $615
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $665
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $608
  \u5e02\u573a\u8d44\u8baf · 2026/9/25
• 评级变动
  A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $633
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX), Alumis Inc. (ALMS) and Medtronic (MDT)
  TipRanks · 2026/9/2
• 评级变动
  Citi Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $585
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  Scotiabank Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $558
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $672
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  William Blair Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  Stifel Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Maintains Target Price $500
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $576
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $558 to $617
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  J.P. Morgan Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $560
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Maze Therapeutics, Inc. (MAZE)
  TipRanks · 2026/9/22
• 评级变动
  BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $672
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  BMO Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• 评级变动
  RBC Capital Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $570
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Morgan Stanley Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $665
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Maxim Group Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $575
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• News On Crinetics Pharmaceuticals Inc. (CRNX) Now Under VRTX
  Dow Jones · 9/2
• Vertex Pharmaceuticals Names Jonathan Poole Chief Financial Officer, Effective Jan. 1 VRTX
  Dow Jones · 9/1

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。